Published date: 11 March 2022

Last edited date: 29 October 2024

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 19 November 2021, 11am

Contract summary

Industry

  • Research and development consultancy services - 73200000

  • Market and economic research; polling and statistics - 79300000

Location of contract

SN2 1FL

Value of contract

£0 to £482,000

Procurement reference

CR21049

Published date

11 March 2022

Closing date

19 November 2021

Closing time

11am

Contract start date

11 February 2022

Contract end date

31 March 2025

Contract type

Supply contract

Procedure type

Call-off from a dynamic purchasing system

A mini-competition or direct purchase from a pre-established dynamic purchasing system.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

Yes

Description

***** THIS IS AN AWARD NOTICE, NOT A CALL FOR COMPETITION *****
This procurement is being concluded following a mini competition under the RM6018 Market Research DPS

Brief Description of Requirement
The UKRI Board are committed to collecting evidence to understand the impacts of the Industrial Strategy Challenge Fund (ISCF) Accelerating Detection of Disease Challenge, (ADD). Bids are invited for an evaluation of this programme to gain insight into the outcomes and impact in the context of the UK and global landscape.
The Industrial Strategy Challenge Fund is part of the Government's Industrial Strategy, the long-term plan to raise productivity and earning power in the UK. The fund is a core pillar in the government's commitment to increase funding in research and development by £4.7 billion over 4 years to strengthen UK science and business. It is focussed on investing in the world-leading research base and highly innovative businesses to address the biggest industrial and societal challenges today.
The Challenge will seek additional consent for active engagement with participants, through the provision of feedback to inform participants of their risk status, any clinically actionable results and opportunities for early intervention. Participants will also be invited to consent to be contacted about future clinical trials which may be of relevance to their risk profile.

The Delivery is split across three phases:
Phase 1: Establishment - Objective is to mitigate risks to the programme and develop a robust operating model through trialling multiple approaches to cohort recruitment and data establishment.
Phase 2: Implementation - Objective is to practically demonstrate that the operating model will effectively deliver the challenge aims.
Phase 3: Scaling - Objective is to take lessons from phase 2 to scale the participant cohorts and deliver a sustainable cohort resource data.

Award information

Awarded date

11 February 2022

Contract start date

11 February 2022

Contract end date

30 September 2025

Total value of contract

£474,447.53

This contract was awarded to 1 supplier.

IPSOS MORI UK LIMITED

Address

3 Thomas More Square
LONDON
E1W 1YW
GB

Reference

Companies House number: 01640855

Value of contract

£474,447.53

Supplier is SME?

No

Supplier is VCSE?

No

Attachments

About the buyer

Contact name

Karl Oakley

Address

Polaris House,North Star Avenue
SWINDON
SN21FF
England

Telephone

01793 867000

Email

professionalservices@uksbs.co.uk

Website

www.uksbs.co.uk